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Peptide transporter 1 (PepT1) is highly expressed in colo-
rectal tumor biopsy specimens and exacerbates tumor
development in murine models of colitis-associated cancer.
The small peptide Lys-Pro-Val, transported by PepT1, de-
creases colon tumorigenesis, suggesting that PepT1 is a
potential therapeutic target for colon cancer.
BACKGROUND & AIMS: The human intestinal peptide trans-
porter 1 (hPepT1), is expressed in the small intestine at low
levels in the healthy colon and up-regulated during inﬂam-
matory bowel disease. hPepT1 plays a role in mouse colitis
and human studies have shown that chronic intestinal
inﬂammation leads to colorectal cancer (colitis-associated
cancer; CAC). Hence, we assessed here the role of PepT1 in
CAC.
METHODS: Mice with hPepT1 overexpression in intestinal
epithelial cells (transgenic [TG]) or PepT1 (PepT1-knockout
[KO]) deletion were used and CAC was induced by azoxy-
methane/dextran sodium sulfate.
RESULTS: TG mice had larger tumor sizes, increased tumor
burdens, and increased intestinal inﬂammation compared
with wild-type (WT) mice. Conversely, tumor number and
size and intestinal inﬂammation were decreased signiﬁcantly
in PepT1-KO mice. Proliferating crypt cells were increased in
TG mice and decreased in PepT1-KO mice. Analysis of human
colonic biopsy specimens showed increased expression of
PepT1 in patients with colorectal cancer, suggesting that
PepT1 might be targeted for the treatment of CAC. The use of
an anti-inﬂammatory tripeptide Lys-Pro-Val (KPV) trans-
ported by PepT1 was able to prevent carcinogenesis in WT
mice. When administered to PepT1-KO mice, KPV did not
trigger any of the inhibitory effect on tumorigenesis observed
in WT mice.
CONCLUSIONS: The observations that PepT1 was highly
expressed in human colorectal tumor and that its overexpression
and deletion in mice increased and decreased colitis-associated
tumorigenesis, respectively, suggest that PepT1 is a potential
therapeutic target for the treatment of colitis-associated tumori-
genesis. (Cell Mol Gastroenterol Hepatol 2016;2:340–357; http://
dx.doi.org/10.1016/j.jcmgh.2016.01.006)Keywords: Colitis-Associated Cancer; Intestinal Inﬂammation;
PepT1; KPV Peptide.
he proton-dependent oligopeptide transporter familyTincludes 4 transporter proteins belonging to the
SLC15A solute carrier group.1 Of them, peptide transporter 1
(PepT1) is a dipeptide and tripeptide transporter that is
expressed primarily in the small intestine of healthy in-
dividuals. PepT1 transports dipeptides/tripeptides from the
lumen into epithelial cells via an inward-directed proton
gradient.2 Under normal physiological condition, intestinal
epithelial cells show apical expression of PepT1, facilitating
the transport and absorption of dipeptides/tripeptides from
endogenous sources in the small intestinal epithelial cells.
There are some controversies regarding whether PepT1 also
is expressed in colonic tissues. Multiple studies have reported
little or no PepT1 expression at messenger RNA (mRNA)
levels in the colons of healthy human beings and rodents.3–10
Other reports have suggested that PepT1 mRNAs were
distributed regionally in the colon, with little or no expres-
sion in proximal colon and an increased expression in the
distal colon.5,6,11 Although another study showed PepT1
protein expression using immunoﬂuorescence in the prox-
imal colon at steady state, the potential transport functions of
colonic PepT1 were not investigated.11
Despite these controversies regarding PepT1 expression
during steady state, the alterations to the expression proﬁle
of PepT1 within the gastrointestinal tract during chronic
inﬂammation have been well described. In patients with
May 2016 PepT1 and Colitis-Associated Cancer 341chronic diseases, such as inﬂammatory bowel disease (IBD)
and short-bowel syndrome, PepT1 expression is up-
regulated in the colon.7,9 Colonic PepT1 is highly
expressed in interleukin (IL)10-/- mice with colitis but not in
Lactobacillus plantarum–treated IL10-/- mice, lacking any
signs of colitis.12 It also was shown that colonic PepT1
expression and function may be induced in mice under
pathologic conditions of the colon from Citrobacter roden-
tium infection.13 In addition to dipeptides/tripeptides from
the diet and other endogenous sources, PepT1 also is able to
transport dipeptides/tripeptides from bacterial origin, such
as N-formyl-methionine-leucine-phenylalanine,14–19 mur-
amyl dipeptide,20 and L-Ala-gamma-D-Glu-mDAP.21 Previ-
ous in vitro results from our laboratory and others have
shown that bacterial peptide transport by PepT1 in colonic
epithelial cells could trigger downstream proinﬂammatory
events, including increased production of inﬂammatory cy-
tokines via a nuclear factor-kB (NF-kB) pathway activation,
and deregulation of colonic microRNA expression.16,20–22
These ﬁndings suggest that PepT1 could play a crucial
role in cell-to-cell communication during colitis. In the
context of IBD, a functional hPepT1 single-nucleotide poly-
morphism (rs2297322) recently was linked to the presence
of IBD in Swedish patients free of the Nucleotide-binding
oligomerization domain-containing protein 2 mutations,23
suggesting that hPepT1 mutation may contribute to the
pathology of IBD. However, additional studies are needed to
explore how this mutation affects the expression and func-
tion of PepT1 during IBD.
In 2 previous studies,17,24 we designed transgenic (TG)
mice that overexpressed PepT1 under the control of the
villin promoter (which confers speciﬁc expression in intes-
tinal epithelial cells) and obtained PepT1-knockout (KO)
mice from Deltagene (San Mateo, CA), to examine how
PepT1 overexpression or deletion affected intestinal
inﬂammation using various models of colitis. Our results
showed that overexpression of PepT1 in intestinal epithelial
cells increased inﬂammation and exacerbated colitis pa-
thology.24 In dextran sodium sulfate (DSS)-treated TG mice,
the degree of pathology was correlated to increased proin-
ﬂammatory cytokine production, increased neutrophil
inﬁltration, and greater weight loss compared with wild-
type (WT) mice.24 Importantly, DSS-treated PepT1-KO
mice developed a moderate colitis compared with WT
mice.25 Histologic examination showed that DSS-treated
PepT1-KO mice showed less proinﬂammatory cytokine
production, neutrophil inﬁltration, and weight loss
compared with DSS-treated WT mice. In addition, knockout
of PepT1 decreased the chemotaxis of immune cells
recruited to the intestine during inﬂammation. Finally,
phenotypes observed with both TG and PepT1-KO mice
were linked to the presence of gut microbiota because they
were attenuated by antibiotic treatment.24,25 Together,
these ﬁndings suggested that PepT1 expression in immune
cells regulates the secretion of proinﬂammatory cytokines
triggered by bacteria and/or bacterial products, thus play-
ing an important role in the induction of colitis.
Colorectal cancer is among the most common human
malignancies26 and has been linked ﬁrmly to chronicintestinal inﬂammation, giving rise to the term colitis-
associated cancer (CAC).7,27 The development of CAC in
patients suffering from IBD is one of the best-characterized
examples of an association between intestinal inﬂammation
and carcinogenesis.28–33 Among patients with ulcerative
colitis, the risk of colon cancer has been found to be as high
as 2% at 10 years, 8% at 20 years, and 18% at 30 years after
the initial diagnosis.28 In contrast, the lifetime risk of spo-
radic colorectal cancer in the United States is only 5%.34 In
the present study, we hypothesized that PepT1 could be
involved in CAC development because of its role in intestinal
inﬂammation. To test this hypothesis, we used both TG and
PepT1-KO mice and used a well-known murine model of CAC
using the carcinogen azoxymethane (AOM), followed by 2
cycles of DSS.35,36 PepT1 has been shown to transport many
types of drugs/prodrugs,37–39 including Lys-Pro-Val (KPV).40
This anti-inﬂammatory tripeptide, which is derived from a-
melanocyte–stimulating hormone, has been shown to have
anti-inﬂammatory properties41,42 and to effectively reduce
chemically induced colitis in mice.40,43,44 Therefore, we hy-
pothesized that KPV may attenuate tumorigenesis in the
AOM/DSS-induced murine model of colon cancer.
In this study, we reported the effect of PepT1 over-
expression and deletion in AOM/DSS-induced carcinogenesis.
We interestingly observed that KPV was able to decrease the
tumor number and the proliferation of malignant colonic
epithelial cells in a PepT1-dependent way, conﬁrming that
PepT1 can be a therapeutic target for the treatment of
colonic inﬂammation and subsequent tumorigenesis.
Materials and Methods
Mice
Eight-week-old female TG, PepT1-KO, and the respective
WT mice with matching C57BL/6 or FVB/NJ background
were used in this study. ApcMin mice (ApcMin/þ), which
contain a germline mutation in the adenomatous polyposis
coli (APC) gene and develop multiple intestinal neoplasia
(Min), were purchased from the Jackson Laboratory (Bar
Harbor, ME). Mice were housed in speciﬁc pathogen-free
conditions and fed ad libitum. All the experiments
involving mice were approved by the Institutional Animal
Care and Use Committee (Georgia State University, Atlanta,
GA; permit numbers A14010 and A14007).
Colitis-Associated Cancer and Intestinal
Adenoma Spontaneous Models
CAC was induced as previously described with some
modiﬁcations.45 Mice were injected intraperitoneally with
AOM (10 mg/kg body weight) (Sigma-Aldrich, St. Louis, MO)
diluted in phosphate-buffered saline (10 mg/kg) and
maintained on regular diet and water for 5 days. Mice then
were subjected to 2 cycles of DSS treatment (MP Bio-
medicals, Solon, OH), in which each cycle consisted of 2.5%
DSS for 7 days followed by a 14-day recovery period with
regular water. Mice were killed by CO2 asphyxiation. Colonic
tumors were counted and measured using a dissecting mi-
croscope. Colonic tumors were counted and grouped by size
as follows: less than 1, 1–2, and more than 2 mm. The total
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tumor burden index.
In experiments testing the efﬁcacy of KPV (Biopeptide Co,
Inc, San Diego, CA) the earlier-described protocol was used
with slight modiﬁcations. Five days after AOM injections (10
mg/kg or 15 mg/kg to WT or PepT1-KO, respectively), WT or
PepT1-KO mice were given 3% DSS with or without KPV for
7 days, followed by 14 days of normal drinking water, then
2.5% or 3% DSS in WT or PepT1-KO mice, respectively, with
or without KPV for 7 days, followed by 14 days of normal
drinking water. The KPV-treated group received 100 mmol/L
KPV in their drinking water along with the DSS during both
DSS cycles. While receiving DSS treatment the mice were
weighed daily to ensure that mice did not lose more than
20% of their original body weight.
From 5 to 18 weeks of age, APCMin/þ mice were treated
with KPV diluted to 100 mmol/L in the drinking water. Mice
were killed at 18 weeks of age by CO2 asphyxiation. The
entire small intestine and colon were dissected longitudi-
nally. Intestinal tissues were examined under a dissecting
microscope and counted for the presence of adenomas.
Intestinal adenomas were counted and grouped by size as
follows: less than 1, 1–2, and more than 2 mm.
Human Colon Tissue Microarray
Human colon tissue array slides were purchased from US
Biomax, Inc. (Rockville, MD). The microarray slide consisted
of 75 samples in duplicates of normal, reactive, and
cancerous (different grades and stages) colon tissues. The
grading system of the tumor was as follows: grade 1 or well
differentiated, cells appear normal and are not growing
rapidly; grade 2 or moderately differentiated, cells appear
slightly different than normal; grade 3 or poorly differenti-
ated, cells appear abnormal and tend to grow and spread
more aggressively; grade 4 or undifferentiated, features are
unremarkably different from that of undifferentiated can-
cers of other organs. The previously described antibody
against hPepT17 was used to stain the array slides at US
Biomax, Inc, and subsequent imagings were performed by
US Biomax, Inc, employees, which then were sent to our
laboratory for further analysis of epithelial hPepT1 staining
(rabbit h-PepT1, dilution 1:3000). Images then were scored
according to 2 parameters (from 0 to 2): the intensity of the
staining: 0, absence of PepT1-positive cells; 1, low-intensity
staining; or 2, high-intensity staining; and the areas of
positive cells in the epithelium: 0, absence of PepT1-positive
cell; 1, less than the half of the epithelium was PepT1 pos-
itive; or 2, half or more of the epithelium was PepT1 posi-
tive. The intensity was indexed by the surface parameter
giving one ﬁnal score for each slide.H&E Staining of Colonic Tissue
Mouse colons were ﬁxed in 10%-buffered formalin for
24 hours at room temperature and then embedded in
parafﬁn. Tissues were sectioned at 5-mm thickness and
stained with H&E using standard protocols. Images were
acquired using an Olympus microscope equipped with a
DP-23 digital camera (Olympus, Pittsburgh, PA).Immunohistochemistry
Mouse colons were ﬁxed in formalin and parafﬁn-
embedded. For Ki67, b-catenin, and PepT1 staining, sections
were deparafﬁnized. Sections were incubated in sodium cit-
rate buffer (pH 6.0) and cooked in a pressure cooker for 10
minutes for antigen retrieval. Sections then were blocked with
5% goat serum in Tris-buffered saline followed by a 1-hour
incubation with anti-Ki67 (1:100; Vector Laboratories, Bur-
lingame, CA), anti–b-catenin (1:1000; Cell Signaling, Danvers,
MA), or anti-mPepT1 at 37C. After washing with Tris-
buffered saline, sections were treated with appropriate bio-
tinylated secondary antibodies for 30 minutes at 37C, and
color development was performed using the Vectastain ABC
kit (Vector Laboratories). Sections then were counterstained
with hematoxylin, dehydrated, and coverslipped. Images were
acquired using an Olympus microscope equipped with a DP-
23 digital camera. Ki67-positive cells were counted per crypt.
Terminal Deoxynucleotidyl Transferase–Mediated
Deoxyuridine Triphosphate Nick-End
Labeling Staining
To quantitate the number of apoptotic cells in colonic
epithelial cells, parafﬁn sections were deparafﬁnized and
stained for apoptotic nuclei according to the manufacturer’s
instructions using the In Situ Cell Death Detection Kit
(Roche Diagnostics, Indianapolis, IN). Images were acquired
using an Olympus microscope equipped with a Hamamatsu
black and white ORCA-03G digital camera. Terminal deox-
ynucleotidyl transferase–mediated deoxyuridine triphos-
phate nick-end labeling (TUNEL)-positive cells that
overlapped with 40,6-diamidino-2-phenylindole nuclear
staining were counted per crypt.
Cytokine Expression Levels
RNA extraction and real-time reverse-transcription
polymerase chain reaction. Total RNA was extracted
from colonic tissues using the RNeasy mini Kit (Qiagen,
Valencia, CA) according to the manufacturer’s instructions.
Yield and quality of RNA were veriﬁed with a Synergy 2
plate reader (BioTek, Winooski, VT). Complementary DNA
was generated from the earlier-described total RNA isolated
using the Maxima ﬁrst-strand complementary DNA synthesis
kit (Thermo Scientiﬁc, Lafayette, CO). mRNA expression was
quantiﬁed by quantitative real-time reverse-transcription
polymerase chain reaction using Maxima SYBR green/ROX
(6-carboxyl-X-rhodamine) quantitative polymerase chain
reaction Master Mix (Thermo Scientiﬁc) and the following
sense and antisense primers: IL6: 5’-ACAAGTCGGAGGCT
TAATTACACAT-3’ and 5’-TTGCCATTGCACAACTCTTTTC-3’;
CXCL2: 5’-CACTCTCAAGGGCGGTCAAA-3’ and 5’-TACGATC-
CAGGCTTCCCGGGT-3’; IL22: 5’-GTCAACCGCACCTTTATGCT-3’
and 5’-GTTGAGCACCTGCTTCATCA-3’; IL10: 5’-GGTTGCCA
AGCCTTATCGGA-3’ and 5’-CTTCTCACCCAGGGAATTCA-3’;
tumor necrosis factor a: 5’-AGGCTGCCCCGACTACGT-3’ and
5’-GACTTTCTCCTGGTATGAGATAGCAAA-3’; and 36B4:
5’-TCCAGGCTTTGGGCATCA-3’ and 5’-CTTTATCAGCTGCA
CATCACTCAGA-3’. Results were normalized by using the
36B4 housekeeping gene.
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Whole-colon lysates were made by homogenizing a small
piece of distal colon in radioimmunoprecipitation assay
buffer plus Halt phosphatase and protease inhibitor cocktail
(Thermo Scientiﬁc, Inc). Fifty micrograms of lysate per well
were resolved on polyacrylamide gradient gels and trans-
ferred to nitrocellulose membranes (Bio-Rad, Hercules, CA).
Membranes were probed with relevant primary antibodies,
including b-catenin, phosphorylated–inhibitor of kB kinase
(Ikk-a/b), and b-actin (Cell Signaling), mouse PepT1
(mPepT1), phosphorylated–extracellular signal-regulated
kinase (ERK)1/2, and total ERK1/2 (Santa Cruz Biotech-
nology, Inc, Santa Cruz, CA), followed by incubation with
appropriate horseradish-peroxidase–conjugated secondary
antibodies (GE Healthcare Biosciences, Pittsburgh, PA).
Blots were developed using enhanced chemiluminescence
Western Blot detection reagents (GE Healthcare Bio-
sciences). Densitometry quantiﬁcations were performed
using the software Quantity One (Bio-Rad).Statistical Analysis
Data are presented as means ± SEM. Statistical analysis
for signiﬁcance was determined using an analysis of vari-
ance test followed by a Bonferroni post-test (GraphPad
Prism, La Jolla, CA).
Results
Tumor Growth Is Increased in Mice That
Overexpress PepT1 in Intestinal Epithelial Cells
We ﬁrst examined if PepT1 overexpression in the colon
could contribute to the development of CAC because it was
shown previously that TG mice had increased inﬂammation
and exacerbated pathologies during acute colitis.24 Our
laboratory previously generated TG mice that overexpress
PepT1 under the control of the villin promoter,24 which is
active primarily in intestinal epithelial cells. When these
mice were treated with AOM/DSS, they tended to develop
an increased number of tumors compared with WT mice,
although this did not reach statistical signiﬁcance (P ¼ .06),
reﬂecting an important variability between individuals
(Figure 1A and B). The number of large tumors (>2 mm2)
was highly increased in TG vs WT mice (Figure 1C), as was
the overall tumor burden index (ie, the total area of tumors
per colon) (Figure 1D), which is indicative of increasedFigure 1. (See previous page). Inﬂammation and tumor grow
intestinal epithelial cells. FVB/NJ WT and TG mice were in
maintained for 7 days, and then subjected to a 2-cycle DSS tre
days of H2O). (A) Representative colon samples were obtained
protocol. (B) Number of tumors per mouse. (C) Tumor size was d
micrometer. The tumor size distribution was graphed. (D) Tumor
tumor burden index. (E) AOM/DSS-treated WT and TG mice w
once per week during the 2-week recovery period after each D
the original day 0 weights. (F) Colon lengths of AOM/DSS-treate
colonic sections from WT or TG mice that received AOM/DSS
Il22, Il10, and Tnf-a were quantiﬁed by quantitative real-time rev
to mRNA levels of the ribosomal protein, 36B4. Values are me
ﬂammatory cell inﬁltration. *P < .05, **P < .01, and ***P < .001susceptibility to tumorigenesis in TG mice, with an
enhanced tumor growth and/or tumor cell survival. Despite
the absence of any difference in body weight loss between
WT and TG mice during the AOM/DSS protocol (Figure 1E),
the colon lengths were decreased in TG mice compared with
WT mice treated by AOM/DSS, showing that the TG mice
were more susceptible to colitis (Figure 1F). Histologic
examination showed the presence of larger adenomas and
increased areas of inﬂammatory cell inﬁltration (arrow,
Figure 1G) in colonic sections from AOM/DSS-treated TG
and WT mice (Figure 1G), with increased dysplasia, aberrant
crypt foci, and cellular inﬁltration in the colonic epithelia of
AOM/DSS-treated TG mice compared with WT mice. Histo-
logically, we did not observe any difference between water-
treated (control) TG and WT mice. Next, we determined the
mRNA expression levels of proinﬂammatory cytokines and
chemokines and found the levels of Il6, Cxcl2, and Il22 to be
signiﬁcantly higher in AOM/DSS-treated TG mice compared
with treated WT mice (Figure 1H), supporting the previous
observation that TG mice were more sensitive to intestinal
inﬂammation and tumorigenesis induced by AOM/DSS
treatment. Interestingly, the expression level of mRNA
encoding tumor necrosis factor a, a proinﬂammatory cyto-
kine reported to have an increased expression in colitis and
CAC,46 did not differ signiﬁcantly between TG and WT mice
(Figure 1H). The anti-inﬂammatory cytokine IL10 expres-
sion was decreased in AOM/DSS-treated TG mice compared
with similarly treated WT mice (Figure 1H). In control
(water-treated) TG and WT mice, no signiﬁcant difference of
these cytokine levels were observed (Figure 1H). Taken
together, these data indicate that TG mice are more sus-
ceptible to AOM/DSS treatment than WT mice, suggesting a
potential role of PepT1 in the initiation and exacerbation of
cancer development.
Overexpression of hPepT1 Deregulates
Proliferation and Apoptosis
The increase in tumor burden and average tumor size in
TG mice suggested that they may be subjected to increased
cell proliferation compared with WT mice. Proliferation of
the colonic epithelial cells was analyzed using an antibody
against the nuclear marker Ki67. No signiﬁcant difference in
the cellular proliferation between water-treated WT and TG
mice was observed (Figure 2A and B). However, after AOM/
DSS treatment, the number of Ki67-positive cells wasth is increased in mice that overexpress PepT1 in their
jected intraperitoneally with AOM (10 mg/kg body weight),
atment (each cycle consisted of 7 days of 2.5% DSS and 14
from each experimental group at the end of the AOM/DSS
etermined using a dissecting microscope ﬁtted with an ocular
areas for each colon were summed and were presented as the
ere weighed on day 0, daily during each DSS treatment, and
SS treatment. The graph represents the percentage values of
d WT and TG mice. (G) Representative images of H&E-stained
or water (control). (H) The colonic mRNA levels of Il6, Cxcl-2,
erse-transcription polymerase chain reaction and normalized
ans ± SEM (n ¼ 5 per group). Scale bar: 100 mm. Arrow, in-
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higher level in TG mice compared with WT mice (Figure 2A
and B). This observation indicates that overexpression of
PepT1 in intestinal epithelial cells exacerbates the AOM/
DSS-induced proliferation of crypt cells in the colonic
epithelium. Ki67-positive cells were highly prevalent in the
colon tumors of both WT and TG mice (data not shown). In
addition, a TUNEL-based quantiﬁcation of apoptosis in
colonic sections from WT and TG mice showed that the
epithelia of AOM/DSS-treated WT mice had signiﬁcantly
more TUNEL-positive cells compared with treated TG mice
(Figure 2C and D). Although AOM/DSS treatment increased
the number of apoptotic cells in both WT and TG mice, the
fold change was signiﬁcantly higher in the former
(Figure 2D), indicating that PepT1 overexpression in
epithelial cells minimized AOM/DSS-induced apoptosis in
the colonic epithelia. Together, these data showed that
PepT1 overexpression in intestinal epithelia may induce
various pathways that lead to increased proliferation and/
or decreased apoptosis of colonic epithelial cells, thereby
potentially contributing to the increased tumor burden
observed in TG mice.Overexpression of hPepT1 Alters Tumorigenesis
Signaling Pathways
Several signaling pathways have been associated with
the regulation of tumorigenesis in the AOM/DSS CAC mouse
model and human CAC. Among them, b-catenin is an onco-
genic protein that plays important roles in cell adhesion and
in a co-transcriptional activation of genes of the Wnt
signaling pathway (eg, c-myc, cyclooxygenase-2, metal-
loproteinase-7, and cyclin D1).47 AOM induces mutations of
b-catenin at speciﬁc serine and threonine residues that are
targeted by Glycogen synthase kinase-3b phosphorylation,
leading to the cellular accumulation of b-catenin.35 b-cat-
enin immunohistochemical staining showed that the levels
of free b-catenin were increased in the cytoplasm of tumor
cells from AOM/DSS-treated WT and TG mice compared
with control (water-treated) animals, in which the majority
of b-catenin staining was associated with the cellular
membranes (Figure 2E). We also observed an increased
nuclear accumulation of b-catenin in tumor cells from TG
mice compared with WT mice (Figure 2E), suggesting that
the transcription of b-catenin may be enhanced in these cells.
Consistent with these results, AOM/DSS-treated WT and TG
mice had increased levels of b-catenin compared with theirFigure 2. (See previous page). Overexpression of hPepT1 inc
apoptosis, and alters tumorigenesis signaling pathways. (
sections from WT and TG mice treated with AOM/DSS or wat
proliferation marker Ki67. (B) Ki67þ cells were counted and avera
Apoptotic colonic epithelial cells were quantiﬁed using a TUNE
stained with 40,6-diamidino-2-phenylindole (blue). (D) Cells positi
were counted and averaged per crypt. Values are means ± SEM
immunohistochemical analysis of colonic tissue sections from W
protein levels of phosphorylated IkkB-a/b, phosphorylated IkB-a
colons of WT or TG mice treated with AOM/DSS or water alo
densitometric quantiﬁcations of Western blot normalized to b-awater-treated counterparts, and b-catenin expression was
slightly higher in colon lysates from TG mice compared
with WT mice, as shown in the densitometric analysis of
Western blot (Figure 2F and G). The NF-kB and mitogen-
activated protein kinase pathways also have been impli-
cated in colon tumorigenesis,35,48 so we next examined
associated signaling partners of these pathways by West-
ern blot. Levels of phosphorylated Ikk-a/b and phos-
phorylated inhibitor of kB (IkB-a) were highly increased in
AOM/DSS-treated TG mice, but only marginally in
comparably treated WT mice (Figure 2F and G), suggesting
that NF-kB signaling is enhanced in AOM/DSS-treated TG
mice compared with WT mice. Finally, we observed
increased levels of phosphorylated ERK1/2 in AOM/DSS-
treated WT and TG mice compared with their respective
water controls (Figure 2F and G), but found no signiﬁcant
AOM/DSS treatment effect between the 2 genotypes, sug-
gesting that this pathway was not be required for the
increased tumor growth observed in PepT1 TG mice.Tumorigenesis is Decreased in
PepT1-Deﬁcient Mice
Next, we investigated whether the absence of PepT1
could protect from AOM/DSS-induced CAC phenotype. After
AOM/DSS treatment, PepT1-KO mice developed signiﬁ-
cantly fewer tumors (of all sizes) compared with similarly
treated WT mice (Figure 3A–C). Consistent with these data,
the overall tumor burden was signiﬁcantly lower in AOM/
DSS-treated PepT1-KO mice compared with AOM/DSS-
treated WT mice (Figure 3D). These data suggest that, in
the absence of PepT1, mice were protected from tumor
initiation and growth. Because intestinal inﬂammation is
known to be a central factor in the initiation and develop-
ment of colon tumors, we next measured various parame-
ters of inﬂammation after the induction of CAC in WT and
PepT1-KO mice. Monitoring of body weight showed that WT
mice underwent a dramatic weight loss during the ﬁrst cycle
of DSS, whereas no such effect was observed in PepT1-KO
mice (Figure 3E). The colons were longer in PepT1-KO
AOM/DSS-treated compared with the WT counterpart,
conﬁrming that the PepT1-KO mice were more resistant to
colitis than WT mice (Figure 3F). Histologic examination
showed the presence of large adenomas with major
lymphocyte inﬁltration in colonic sections from AOM/DSS-
treated WT mice (Figure 3G), whereas no lymphocyte
inﬁltration or adenoma was detected in AOM/DSS-treatedreases colonic epithelial proliferation, decreases epithelial
A) The levels of epithelial cell proliferation in colonic tissue
er alone were assessed by immunohistochemistry using the
ged per crypt. Values are means ± SEM (n ¼ 5 per group). (C)
L assay (ﬂuorescein isothiocyanate, green) and nuclei were
ve for both TUNEL and 40,6-diamidino-2-phenylindole staining
(n ¼ 5 per group). (E) The levels of b-catenin were assessed by
T and TG mice treated with AOM/DSS or water alone. (F) The
, b-catenin, phosphorylated-ERK1/2, and total ERK1/2 in the
ne were analyzed by Western blot. (G) Bar graph represents
ctin. Scale bars: 50 mm. *P < .05, ***P < .001.
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ference of these parameters between control (water-
treated) PepT1-KO and WT mice (Figure 3G). Next, we
examined the mRNA levels of proinﬂammatory cytokines
and chemokines in WT and PepT1-KO mice with or without
CAC induction. We found that the expression levels of Il6,
Cxcl2, Il22, and Tnf-a were increased signiﬁcantly in WT
mice after AOM/DSS treatment. Importantly, although Il-6
and Cxcl-2 were increased only moderately in AOM/DSS-
treated PepT1-KO mice, levels of Il22 and Tnf-a were
increased signiﬁcantly (Figure 3H). The expression level of
Il10 in PepT1-KO mice tended to be lower than that in WT
mice, but no signiﬁcant difference was observed regardless
of the genotype or treatment (Figure 3H). These results
showed that AOM/DSS-associated intestinal inﬂammation
was attenuated in PepT1-KO mice compared with WT mice.
Taken together, these data indicate that PepT1-KO mice
were protected against AOM/DSS-induced tumorigenesis
through a partial inhibition of tumorigenic intestinal
inﬂammation. This supports our hypothesis that PepT1
plays a central role in the initiation and exacerbation of CAC
in mice.PepT1-KO Mice Elicit a Beneﬁcial Balance of
Proliferation and Apoptosis in the Colonic
Mucosa Associated With Inhibition of
Tumorigenesis-Related Signaling
Ki67 staining showed that there was no signiﬁcant dif-
ference in cellular proliferation among water-treated (con-
trol) WT and PepT1 mice, as well as AOM/DSS-treated
PepT1-KO mice, whereas AOM/DSS-treated WT mice had
signiﬁcantly more Ki67-positive cells per crypt (Figure 4A
and B). This indicates that, in the absence of PepT1, prolif-
eration of crypt epithelial cells was inhibited. Importantly,
Ki67-positive cells were located in the entire crypt in WT
mice, whereas they were located only in basal crypts in
PepT1-KO mice, attesting to the extensive proliferation
occurring in WT mice when subjected to AOM/DSS. Next, we
used TUNEL staining to determine the levels of apoptosis in
colonic mucosa sections from WT and PepT1-KO mice. The
basal level of apoptosis was slightly but signiﬁcantly higher in
PepT1-KO mice compared with WT mice, and the number of
apoptotic cells in the epithelia of WT and, to a lesser extent,
PepT1-KO mice was signiﬁcantly greater after AOM/DSSFigure 3. (See previous page). Inﬂammation and tumor grow
were injected intraperitoneally with AOM (10 mg/kg body weigh
treatment, with each cycle consisting of 7 days of 2.5% DSS a
from each experimental group at the end of the AOM/DSS pro
determined using a dissecting microscope ﬁtted with an ocul
Tumor areas were summed for each colon, and were presente
PepT1-KO mice were weighed on day 0, daily during each DSS
recovery period. The graph represents the percentage values o
treated WT and PepT1-KO mice. (G) Representative images o
treated with AOM/DSS or water alone. (H) The colonic mRNA
(TNF)-a were quantiﬁed by quantitative real-time reverse-trans
levels of the ribosomal protein, 36B4. Values are means ± SEM
cell inﬁltration. *P < .05, **P < .01.treatment (Figure 4C and D). Thus, PepT1 deﬁciency appears
to be protective against the proliferative and abnormal
apoptosis status induced by AOM/DSS treatment.
To investigate whether PepT1 deﬁciency inhibits
tumorigenesis signaling pathways, the accumulation of
proteins involved in tumorigenesis was analyzed by West-
ern blot. Increased levels of phosphorylated Ikk-a/b were
observed in AOM/DSS-treated PepT1-KO mice compared
with AOM/DSS-treated WT mice, whereas no difference was
observed in the levels of phosphorylated IkB-a and total
IkB-a between the 2 genotypes (Figure 4E and F), suggest-
ing that the inhibition of the NF-kB pathway was not the
mechanism underlying the attenuated tumor growth asso-
ciated with PepT1 deﬁciency. Compared with the relevant
controls, b-catenin levels were unaltered in AOM/DSS-
treated WT mice and comparably treated PepT1-KO mice,
whereas the levels of phosphorylated ERK1/2 were
increased drastically in AOM/DSS-treated WT mice but
remained unchanged in AOM/DSS-treated PepT1-KO mice
(Figure 4E and F). This ﬁnding suggests that PepT1 deﬁ-
ciency may antagonize and/or protect from the AOM/DSS-
induced ERK pathway. Together, these results suggest that
inhibition of the tumor-growth–promoting ERK
pathway49,50 might be involved in the inhibition of AOM/
DSS-associated tumor growth observed in PepT1-KO mice.KPV Prevents Intestinal Inﬂammation and
Tumorigenesis During Colitis-Associated
Carcinogenesis in a PepT1-Dependent Manner
The analysis of PepT1 expression at the mRNA and pro-
tein levels both indicated that PepT1 levels were up-
regulated in the colons of AOM/DSS-treated WT mice
(Figure 5A and C). WT mice treated with AOM/DSS had
increased PepT1 staining in epithelial cells lining the colon
compared with water-treated (control) mice (Figure 5B).
These immunohistochemical data were veriﬁed further by
Western blot analysis of whole-colon lysates (Figure 5C), in
which greater PepT1 expression was found in the colon of
AOM/DSS-treated WT animals. Therefore, we predicted that
colonic PepT1 also would be up-regulated in colon cancer
patients, as previously described for bladder cancer
specimens at mRNA levels.51 To determine if PepT1 was
up-regulated during human disease, we analyzed a
human tissue microarray, stained for hPepT1, that includedth is reduced in PepT1-KO mice. WT and PepT1-KO mice
t) and maintained for 7 days, then subjected to 2-cycle DSS
nd 14 days of H2O. (A) Representative colons were obtained
tocol. (B) Number of tumors per mouse. (C) Tumor size was
ar micrometer. The tumor size distribution was graphed. (D)
d as the tumor burden index. (E) AOM/DSS-treated WT and
treatment, and once per week during each 2-week post-DSS
f the original day 0 weights. (F) Colon lengths of AOM/DSS-
f H&E-stained colonic sections from WT or PepT1-KO mice
levels of IL6, CXCL-2, IL22, IL10, and tumor necrosis factor
cription polymerase chain reaction and normalized to mRNA
(n ¼ 4–11 per group). Scale bar: 50 mm. Arrow: inﬂammatory
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Figure 5. PepT1 expression is up-regulated during colon cancer in mice. (A) The colonic mRNA levels of PepT1 were
quantiﬁed by quantitative real-time reverse-transcription polymerase chain reaction and normalized to mRNA levels of the
ribosomal protein 36B4. Values are means ± SEM (n ¼ 8–9 per group). (B) Immunohistochemical analysis of mouse PepT1 was
performed on colonic tissue sections from WT mice treated with AOM (10 mg/kg body weight) plus 2 cycles of 2.5% DSS, or
water alone. Microscopic images were taken at 20 magniﬁcation. (C) Whole-colon lysates were used in Western blot ana-
lyses for mouse PepT1. b-actin was detected as the loading control. **P < .01, ***P < .001. GAPDH, glyceraldehyde-3-
phosphate dehydrogenase.
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cancer patients with various stages of malignancies from
grades I to III, as well as patients with benign colon tumors
(male and female patients ranging in age from 19 to 92 years).
The images then were analyzed and scored for epithelial/
tumor cell hPepT1 staining. Most of the colon cancer patients
showed hPepT1 staining in their epithelial and/or tumor cells
(Figure 6). In normal colon samples, some hPepT1 staining
was observed in cells surrounding the epithelium, which most
likely were immune cells.15 In the benign colon adenoma,
hPepT1 staining was observed in limited areas of epithelia,
probably as a consequence of inﬂammation, as previously
reported.7 Importantly, the majority of the colon tumor sam-
ples showed increased staining relative to both normal andFigure 4. (See previous page). PepT1 knockout decreases co
and inhibits tumorigenesis-related signaling. (A) The levels of
and PepT1-KO mice treated with AOM/DSS or water alone we
marker Ki67. (B) Ki67þ cells were counted and averaged per cryp
colonic epithelial cells were quantiﬁed using a TUNEL assay (ﬂu
40,6-diamidino-2-phenylindole (blue). (D) Cells positive for both
averaged per crypt. Values are means ± SEM (n ¼ 5–9 per gro
phorylated and total IkB-a, b-catenin, phosphorylated-ERK1/2
treated with AOM/DSS or water alone were analyzed by Western
Western blot normalized to b-actin. Scale bars: 50 mm. *P < .0benign tissues (Figure 6B). The speciﬁc up-regulation of
PepT1 in tumor tissues showed the potential use of PepT1
transporter activity in the treatment of CAC.
Several studies have shown previously that KPV tripep-
tide decreased intestinal inﬂammation and attenuated DSS-
induced colitis,40,43,44 suggesting tripeptide as a valuable
therapeutic tool against colitis and associated carcinogen-
esis. We previously showed that KPV was transported via
PepT1 in vitro in Caco-2/brush border expressing (BBE)
cells.40 We then hypothesized that KPV may help to prevent
colon tumorigenesis in the AOM/DSS-induced CAC model.
To test this hypothesis, WT mice were treated with AOM/
DSS or AOM/DSS þ KPV, showing that WT mice given KPV
in conjunction with AOM/DSS showed a drastic decrease inlonic epithelial proliferation, modiﬁes epithelial apoptosis,
epithelial cell proliferation in colonic tissue sections from WT
re assessed by immunohistochemistry using the proliferation
t. Values are means ± SEM (n ¼ 5–9 per group). (C) Apoptotic
orescein isothiocyanate, green), and nuclei were stained with
TUNEL and 40,6-diamidino-2-phenylindole were counted and
up). (E) The protein levels of phosphorylated IkkB-ab, phos-
, and total ERK1/2 in the colons of WT or PepT1-KO mice
blot. (F) Bar graph represents densitometry quantiﬁcations of
5, **P < .01, and ***P < .001.
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Figure 6. PepT1 expression is up-regulated during colon cancer. (A) Human PepT1 antibody was used to observe PepT1
levels in a human tissue microarray counterstained with hematoxylin. The tissue microarray included samples from normal
patients, patients with benign colon tumors, and colon cancer patients with various stages of colon adenocarcinoma. (B) The
anti-human PepT1-stained slides were scored according to 2 parameters (from 0 to 2): the intensity of the staining: 0, absence
of PepT1-positive cells; 1, low-intensity staining; and 2, high-intensity staining; and the area of positive cells in the epithelium:
0, absence of PepT1-positive cells; 1, less than the half of the epithelium is PepT1 positive; and 2, half or more of the
epithelium is PepT1 positive. The intensity was indexed by the surface parameter giving one ﬁnal score for each slide. Scale
bars: 100 mm. *P < .05.
May 2016 PepT1 and Colitis-Associated Cancer 351colon tumorigenesis, as shown by tumor numbers, sizes, and
overall colonic tumor burdens (Figure 7A–D), compared
with AOM/DSS-only–treated animals. Although both groups
of mice lost similar amounts of weight during DSS treatment
(Figure 7E), KPV-treated mice showed decreased
inﬂammation, fewer aberrant crypt foci, decreased cellular
inﬁltration (as seen on H&E-stained sections), and less
epithelial cell proliferation (ie, fewer Ki67þ cells/crypts)
(Figure 7F–H). To investigate the putative protective effect
of KPV administration in PepT1-KO mice, the colitis-
associated cancer protocol was modiﬁed slightly based on
the relative low penetrance of the disease in PepT1-deﬁcient
animals (Figure 3). AOM concentration was increased to
15 mg/kg and DSS to 3% to favor tumor development. We
observed that, unlike WT mice, PepT1-KO animals were not
protected from tumorigenesis by KPV administration, as
shown by tumor numbers, sizes, tumor burdens, and mouse
body weights that were not changed signiﬁcantly between
AOM/DSS and AOM/DSS þ KPV groups (Figure 8A–E).
Despite the statistical nonsigniﬁcance, a trend for a
decreased tumor burden index was seen in the KPV-treated
group. These data importantly show that KPV acts at least in
part through PepT1, opening an important potential thera-
peutic avenue for the treatment of colonic inﬂammation and
subsequent tumorigenesis.KPV was shown to decrease tumorigenesis in a colitis-
associated model of cancer. We next wanted to know
whether KPV also would reduce tumorigenesis in a nonin-
ﬂammatory model. For this purpose, APCMin/þ mice, a
genetic model of intestinal adenocarcinoma that sponta-
neously develops adenomas mainly in the small intestine,
were treated with KPV for 13 weeks. As presented in
Figure 9, KPV did not decrease the tumor burden in the
small intestine or in the colon. However, our results
importantly showed that intestinal inﬂammation, assessed
by lipocalin-2 measurement, was decreased by KPV treat-
ment, conﬁrming the anti-inﬂammatory effect of KPV in this
model. These results indicated that the decrease of intes-
tinal inﬂammation induced by KPV, observed in Figure 7,
was not sufﬁcient to decrease the tumor formation in a
genetic model of tumorigenesis. However, genetic colon
carcinoma models only represent 2%–5% of all colon
cancers52 and have a severe tumor development even in
germ-free mice and a dramatically decreased basal intes-
tinal inﬂammation.53 Therefore, although the inhibition of
intestinal inﬂammation via the KPV/PepT1 pathway was
not sufﬁcient to inhibit tumorigenesis in such a stringent
model as the APCMin/þ mice, KPV showed a promising
potential for inhibiting inﬂammation in various models of
colon cancer.
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Figure 7. KPV decreases inﬂammation and tumorigenesis during CAC. WT mice were treated with AOM followed by 2
cycles of DSS, during which mice were co-treated with or without 100 mmol/L KPV. (A) Representative colons were obtained
from each experimental group at the end of the AOM/DSS protocol. (B) Number of tumors per mouse. (C) Tumor size was
determined using a dissecting microscope ﬁtted with an ocular micrometer. The tumor size distribution was graphed. (D) The
tumor areas of each colon were summed, and they were presented as the tumor burden index. (E) Mice were weighed on day
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KPV treatment. The graph represents the percentage values of the original day 0 weight. (F) Representative images of H&E-
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Figure 8. KPV inhibitory effect is abrogated in PepT1-KO mice. PepT1-KO mice were treated with AOM followed by 2
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per group).
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The present study showed that PepT1 overexpression
leads to increased inﬂammation and colonic tumor burdens
in a murine model of CAC, strongly suggesting that PepT1
plays a crucial role in CAC. Previous reports showed that
PepT1 protein expression was up-regulated in the colon
under the conditions of chronic inﬂammation, such as
IBD7,27; this may increase the interactions between bacterial
peptides and intracellular innate immune receptors (eg,
NOD receptors), thereby triggering the downstream activa-
tion of proinﬂammatory signaling pathways.24,54
In TG mice, we observed up-regulation of proin-
ﬂammatory cytokines/chemokines and down-regulation of
an anti-inﬂammatory cytokine (IL10) compared with WT
mice. It has been reported that IL10-deﬁcient mice develop
spontaneous colitis, and after 3 and 6 months, 25% and
60% of the mice develop adenocarcinomas, respectively.55
Thus, IL10 appears to play an important role in intestinal
inﬂammation. Interestingly, colonic PepT1 protein was
expressed in IL10-/- mice that showed signs of colitis, but
not in noncolitic IL10-/- mice,12 suggesting that PepT1contributes to the development of colitis in this model. In
IL10-deﬁcient mice, tumorigenesis was decreased by the
administration of exogenous IL10, even after colitis had
developed.31,55 After the induction of the CAC tumor model,
we herein found that PepT1-overexpressed TG mice had
increased inﬂammation, larger tumors, and greater overall
tumor burdens compared with WT mice, suggesting that
PepT1 expression in intestinal epithelial cells may enhance
tumor cell growth or survival in the presence of a carcino-
genic assault (here, AOM/DSS treatment). Despite the non-
signiﬁcance (P ¼ .06), a trend for an increased tumor
number was observed in TG mice subjected to AOM/DSS
treatment compared with WT. The observation of a subtle
increase suggested that the tumor initiation was not the
main process being affected by PepT1. Instead, PepT1
appears to enhance the proliferation/survival of tumor cells,
contributing to the presence of larger tumors throughout
the colon. Consistent with this hypothesis, cell proliferation
was increased whereas apoptosis was decreased in the
epithelial crypts of TG mice. The tumor number was
signiﬁcantly lower in PepT1-KO mice than in WT mice,
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Figure 9. KPV does not reduce tumorigenesis in a genetic model of intestinal cancer. APCMin/þ were treated or not with
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Number of colonic adenomas per mouse. (C) Tumor size distribution. (D) Spleen weight and (E) colon length. (F) Lipocalin-2
(LCN-2) was measured in feces collected from 5-week-old, 11-week-old, and 18-week-old mice. Values are means ± SEM
(n ¼ 5–6 per group).
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the protective effect observed in PepT1-KO mice vs the
aggravating effect observed in TG mice. To test this hy-
pothesis, we used Western blot to examine various proteins
involved in the prosurvival, proliferation, and tumorigenesis
signaling pathways. AOM/DSS treatment enhanced the
activation of the NF-kB and Wnt/b-catenin pathways in TG
mice compared with WT mice, but no such change was seen
in PepT1-KO mice. Conversely, phosphorylated ERK1/2 was
similarly up-regulated after AOM/DSS treatment of TG and
WT mice, but this up-regulation was abrogated in PepT1-KO
mice. This suggests that the absence of PepT1 inhibits the
ERK pathway, potentially explaining (at least in part) the
inhibition of tumor development and growth observed in
PepT1-KO mice.
Because colonic PepT1 is expressed at minimal levels in
healthy individuals, treatments that effectively down-
regulate PepT1 expression in IBD or, as shown in our
study, in CAC patients in whom PepT1 is expressed at higher
levels, may attenuate inﬂammation and reduce the risk for
tumorigenesis. For example, treatment of IL10-/- mice with
the probiotic L plantarum reduced PepT1 expression and
activity and attenuated colitis compared with vehicle-
treated IL10-/- animals.12 Alternatively, we showed that
PepT1 was up-regulated in colons of mice with AOM/DSS-
induced CAC and in human colon adenocarcinoma, and
treatments that exploit the transporter activity of PepT1
could increase the effectiveness of particular drugs by
enhancing their bioavailability after oral administration.PepT1 transports several types of peptide-derived drugs,
including antibiotics, inhibitors of angiotensin-converting
enzyme, and anticancer and antiviral drugs.37,38,56 Among
them, the PepT1 substrate and antitumor drug bestatin was
found to decrease cell proliferation, ameliorate tumor
growth,57 inhibit the growth of colon adenocarcinoma, and
decrease the growth of myeloid leukemia C1498 cells
in vivo.58 In this study, we speciﬁcally focused on another
peptide, namely KPV.
KPV, a tripeptide from the C-terminus of a-melanocyte–
stimulating hormone, confers anti-inﬂammatory effects,59,60
acting as a substrate for and actively transported by PepT1
in vitro.40 After stimulation with proinﬂammatory cyto-
kines, Caco2-BBE and Jurkat cells that were co-treated with
KPV showed attenuated NF-kB activation and decreased
proinﬂammatory cytokine production.40 Our data presented
here, importantly show that KPV treatment is able to
decrease AOM/DSS-induced tumorigenesis. This was
occurring in a PepT1-dependent manner because PepT1-KO
animals were not protected from tumorigenesis by KPV
administration. However, a trend for a decreased tumor
burden index still was seen in PepT1-KO in the KPV-treated
group compared with the water control group, pointing out
that, even if mainly PepT1-dependent, KPV also might be
transported by other peptide transporters. KPV still repre-
sents a promising drug for targeting PepT1, as inferred from
a previous study that found a high afﬁnity of hPepT1 for
KPV (Kmw160 mmol/L) in Caco2-BBE cells.40 This Km is
among the lowest Kms reported for hPepT1. For example,
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has a Km of 1 mmol/L or greater in Caco2-BBE cells.61 This
will allow low doses of KPV to be transported efﬁciently by
PepT1. This aspect is of high interest for using this tripep-
tide in clinics for the treatment of IBD or CAC.
IBD-related inﬂammation is believed to increase the risk
of colorectal cancer, but many existing studies have failed to
show a strong positive link between the anti-inﬂammatory
drugs commonly used to treat IBD and a decreased risk of
colon cancer.62 However, a long-term reduction of the
inﬂammation by the use of nonsteroidal anti-inﬂammatory
drugs was associated previously with a protective role
against colorectal cancer.63 In the present study, we re-
ported a time-dependent increase of intestinal inﬂammation
in APCMin/þ. Importantly, even with a limited inhibition of
tumorigenesis in such a stringent model, KPV was sufﬁcient
to decrease the inﬂammation in this model of non–
inﬂammatory-induced carcinogenesis. Therefore, we antici-
pate that the use of KPV before the development of colon
cancer might be of interest as a preventive agent of colonic
carcinogenesis.
Overall, additional studies are warranted to determine
the precise mechanism by which KPV decreases tumori-
genesis in this model, and to test whether this tripeptide
could be beneﬁcial against human CAC.
Finally, several studies have shown that PepT1 is
expressed by cancer cell types beyond colorectal cancer
cells,64–66 including gastric and pancreatic cancer cells.
Thus, the transporter activity of PepT1 in either the small or
large intestine may be used to address these other types of
cancer, and future studies may identify other tumor types
that show increased PepT1 expression.
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